• Adelstein DJ, Li Y, Adams GL. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:9298.

    • Search Google Scholar
    • Export Citation
  • Adelstein DJ, Ridge JA, Gillison ML. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C. Head Neck 2009;31:13931422.

    • Search Google Scholar
    • Export Citation
  • Al-Sarraf M, LeBlanc M, Giri PG. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:13101317.

    • Search Google Scholar
    • Export Citation
  • Bernier J, Cooper JS, Pajak TF. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005;27:843850.

    • Search Google Scholar
    • Export Citation
  • Bernier J, Domenge C, Ozsahin M. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:19451952.

    • Search Google Scholar
    • Export Citation
  • Bourhis J, Overgaard J, Audry H. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843854.

    • Search Google Scholar
    • Export Citation
  • Brizel DM, Albers ME, Fisher SR. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:17981804.

    • Search Google Scholar
    • Export Citation
  • Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:26442652.

    • Search Google Scholar
    • Export Citation
  • Cooper JS, Pajak TF, Forastiere AA. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:19371944.

    • Search Google Scholar
    • Export Citation
  • DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 8th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

    • Search Google Scholar
    • Export Citation
  • Fu KK, Pajak TF, Trotti A. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:716.

    • Search Google Scholar
    • Export Citation
  • Furniss CS, McClean MD, Smith JF. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer 2007;120:23862392.

  • Gillison ML, Koch WM, Capone RB. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709720.

    • Search Google Scholar
    • Export Citation
  • Kutler DI, Patel SG, Shah JP. The role of neck dissection following definitive chemoradiation. Oncology (Williston Park) 2004;18:993998; discussion 999, 1003–1004, 1007.

    • Search Google Scholar
    • Export Citation
  • Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24:26732678.

  • Lefebvre JL, Chevalier D, Luboinski B. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890899.

    • Search Google Scholar
    • Export Citation
  • Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope 2000;110:593602.

  • Pignon JP, Bourhis J, Domenge C. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949955.

    • Search Google Scholar
    • Export Citation
  • Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 2009;19:2934.

  • Vermorken JB, Mesia R, Rivera F. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:11161127.

  • 1

    DeVita V Jr, Lawrence T, Rosenberg S, eds. Cancer: Principles & Practice of Oncology, 8th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

    • Search Google Scholar
    • Export Citation
  • 2

    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277300.

  • 3

    American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010. Available at: http://www.cancer.org/downloads/STT/Cancer_Facts_and_Figures_2010.pdf. Accessed April 12, 2011.

    • Search Google Scholar
    • Export Citation
  • 4

    Gillison ML, Koch WM, Capone RB. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709720.

    • Search Google Scholar
    • Export Citation
  • 5

    Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467475.

    • Search Google Scholar
    • Export Citation
  • 6

    Applebaum KM, Furniss CS, Zeka A. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 2007;99:18011810.

    • Search Google Scholar
    • Export Citation
  • 7

    D’Souza G, Kreimer AR, Viscidi R. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:19441956.

  • 8

    Schlecht NF, Burk RD, Adrien L. Gene expression profiles in HPV-infected head and neck cancer. J Pathol 2007;213:283293.

  • 9

    Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007;110:14291435.

    • Search Google Scholar
    • Export Citation
  • 10

    Adelstein DJ, Ridge JA, Gillison ML. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C. Head Neck 2009;31:13931422.

    • Search Google Scholar
    • Export Citation
  • 11

    Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612619.

    • Search Google Scholar
    • Export Citation
  • 12

    Edge S, Byrd D, Compton C. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.

  • 13

    Greene F, Page D, Fleming I. AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer-Verlag; 2002.

  • 14

    Colasanto JM, Prasad P, Nash MA. Nutritional support of patients undergoing radiation therapy for head and neck cancer. Oncology (Williston Park) 2005;19:371379.

    • Search Google Scholar
    • Export Citation
  • 15

    Schnoll RA, Zhang B, Rue M. Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2003;21:355365.

    • Search Google Scholar
    • Export Citation
  • 16

    Gritz ER, Carr CR, Rapkin D. Predictors of long-term smoking cessation in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1993;2:261270.

    • Search Google Scholar
    • Export Citation
  • 17

    Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23:455468.

  • 18

    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373383.

    • Search Google Scholar
    • Export Citation
  • 19

    Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope 2000;110:593602.

  • 20

    Piccirillo JF, Lacy PD, Basu A, Spitznagel EL. Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg 2002;128:11721179.

    • Search Google Scholar
    • Export Citation
  • 21

    Piccirillo JF. Impact of comorbidity and symptoms on the prognosis of patients with oral carcinoma. Arch Otolaryngol Head Neck Surg 2000;126:10861088.

    • Search Google Scholar
    • Export Citation
  • 22

    Chen AY, Matson LK, Roberts D, Goepfert H. The significance of comorbidity in advanced laryngeal cancer. Head Neck 2001;23:566572.

  • 23

    Singh B, Bhaya M, Stern J. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multiinstitutional study. Laryngoscope 1997;107:14691475.

    • Search Google Scholar
    • Export Citation
  • 24

    Hall SF, Rochon PA, Streiner DL. Measuring comorbidity in patients with head and neck cancer. Laryngoscope 2002;112:19881996.

  • 25

    Hall SF, Groome PA, Rothwell D. The impact of comorbidity on the survival of patients with squamous cell carcinoma of the head and neck. Head Neck 2000;22:317322.

    • Search Google Scholar
    • Export Citation
  • 26

    Ribeiro KC, Kowalski LP, Latorre MR. Impact of comorbidity, symptoms, and patients’ characteristics on the prognosis of oral carcinomas. Arch Otolaryngol Head Neck Surg 2000;126:10791085.

    • Search Google Scholar
    • Export Citation
  • 27

    de Graeff A, de Leeuw JR, Ros WJ. Pretreatment factors predicting quality of life after treatment for head and neck cancer. Head Neck 2000;22:398407.

    • Search Google Scholar
    • Export Citation
  • 28

    Funk GF, Karnell LH, Whitehead S. Free tissue transfer versus pedicled flap cost in head and neck cancer. Otolaryngol Head Neck Surg 2002;127:205212.

    • Search Google Scholar
    • Export Citation
  • 29

    Farwell DG, Reilly DF, Weymuller EA. Predictors of perioperative complications in head and neck patients. Arch Otolaryngol Head Neck Surg 2002;128:505511.

    • Search Google Scholar
    • Export Citation
  • 30

    Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluatin the outcome of diabetes mellitus. J Chronic Dis 1974;27:387404.

    • Search Google Scholar
    • Export Citation
  • 31

    Bang D, Piccirillo J, Littenberg B. The Adult Comorbidity Evaluation-27 (ACE-27) test: a new comorbidity index for patients with cancer [abstract]. J Clin Oncol 2000;(Suppl 1):Abstract 1701.

    • Search Google Scholar
    • Export Citation
  • 32

    Piccirillo J, Costas I, Claybour P. The measurement of comorbidity by cancer registries. J Registry Manag 2003;30:814.

  • 33

    Patrick D, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York, NY: Oxford University Press; 1993.

    • Search Google Scholar
    • Export Citation
  • 34

    Yueh B. Measuring and Reporting Quality of Life in Head and Neck Cancer. McLean, Virginia; 2002.

  • 35

    Rogers SN, Gwanne S, Lowe D. The addition of mood and anxiety domains to the University of Washington quality of life scale. Head Neck 2002;24:521529.

    • Search Google Scholar
    • Export Citation
  • 36

    Bjordal K, Hammerlid E, Ahlner-Elmqvist M. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999;17:10081019.

    • Search Google Scholar
    • Export Citation
  • 37

    Cella D. Manual for the Functional Assessment of Cancer Therapy (FACT) Measurement System (version 4). Chicago: Rush Medical Center; 1997.

    • Search Google Scholar
    • Export Citation
  • 38

    List MA, D’Antonio LL, Cella DF. The Performance Status Scale for head and neck cancer patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer 1996;77:22942301.

    • Search Google Scholar
    • Export Citation
  • 39

    Harrison L, Sessions R, Hong W. Head and Neck Cancer: A Multidisciplinary Approach, 3rd edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2009.

    • Search Google Scholar
    • Export Citation
  • 40

    Robbins KT, Shaha AR, Medina JE. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 2008;134:536538.

    • Search Google Scholar
    • Export Citation
  • 41

    Byers RM. Neck dissection: concepts, controversies, and technique. Semin Surg Oncol 1991;7:913.

  • 42

    Stringer SP. Current concepts in surgical management of neck metastases from head and neck cancer. Oncology (Williston Park) 1995;9:547554.

    • Search Google Scholar
    • Export Citation
  • 43

    Robbins KT, Clayman G, Levine PA. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg 2002;128:751758.

    • Search Google Scholar
    • Export Citation
  • 44

    Candela FC, Kothari K, Shah JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck 1990;12:197203.

    • Search Google Scholar
    • Export Citation
  • 45

    Candela FC, Shah J, Jaques DP, Shah JP. Patterns of cervical node metastases from squamous carcinoma of the larynx. Arch Otolaryngol Head Neck Surg 1990;116:432435.

    • Search Google Scholar
    • Export Citation
  • 46

    Shah JP, Candela FC, Poddar AK. The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer 1990;66:109113.

    • Search Google Scholar
    • Export Citation
  • 47

    Ferlito A, Rinaldo A, Silver CE. Elective and therapeutic selective neck dissection. Oral Oncol 2006;42:1425.

  • 48

    Schmitz S, Machiels JP, Weynand B. Results of selective neck dissection in the primary management of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2009;266:437443.

    • Search Google Scholar
    • Export Citation
  • 49

    Patel RS, Clark J, Wyten R. Squamous cell carcinoma from an unknown head and neck primary site: a “selective treatment” approach. Arch Otolaryngol Head Neck Surg 2007;133:12821287.

    • Search Google Scholar
    • Export Citation
  • 50

    Sivanandan R, Kaplan MJ, Lee KJ. Long-term results of 100 consecutive comprehensive neck dissections: implications for selective neck dissections. Arch Otolaryngol Head Neck Surg 2004;130:13691373.

    • Search Google Scholar
    • Export Citation
  • 51

    Liauw SL, Mancuso AA, Amdur RJ. Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. J Clin Oncol 2006;24:14211427.

    • Search Google Scholar
    • Export Citation
  • 52

    Porceddu SV, Jarmolowski E, Hicks RJ. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 2005;27:175181.

    • Search Google Scholar
    • Export Citation
  • 53

    Yao M, Smith RB, Hoffman HT. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys 2009;74:914.

    • Search Google Scholar
    • Export Citation
  • 54

    Lango MN, Myers JN, Garden AS. Controversies in surgical management of the node-positive neck after chemoradiation. Semin Radiat Oncol 2009;19:2428.

    • Search Google Scholar
    • Export Citation
  • 55

    Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210222.

    • Search Google Scholar
    • Export Citation
  • 56

    Corry J, Peters L, Fisher R. N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders-results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck 2008;30:737742.

    • Search Google Scholar
    • Export Citation
  • 57

    Lau H, Phan T, Mackinnon J, Matthews TW. Absence of planned neck dissection for the N2-N3 neck after chemoradiation for locally advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2008;134:257261.

    • Search Google Scholar
    • Export Citation
  • 58

    Ong SC, Schoder H, Lee NY. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008;49:532540.

    • Search Google Scholar
    • Export Citation
  • 59

    Nayak JV, Walvekar RR, Andrade RS. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope 2007;117:21292134.

    • Search Google Scholar
    • Export Citation
  • 60

    Abgral R, Querellou S, Potard G. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:2429.

    • Search Google Scholar
    • Export Citation
  • 61

    Bernier J, Domenge C, Ozsahin M. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:19451952.

    • Search Google Scholar
    • Export Citation
  • 62

    Cooper JS, Pajak TF, Forastiere AA. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:19371944.

    • Search Google Scholar
    • Export Citation
  • 63

    Bernier J, Cooper JS, Pajak TF. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005;27:843850.

    • Search Google Scholar
    • Export Citation
  • 64

    Bachaud JM, Cohen-Jonathan E, Alzieu C. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999104.

    • Search Google Scholar
    • Export Citation
  • 65

    Shah JP, Cendon RA, Farr HW, Strong EW. Carcinoma of the oral cavity. factors affecting treatment failure at the primary site and neck. Am J Surg 1976;132:504507.

    • Search Google Scholar
    • Export Citation
  • 66

    Looser KG, Shah JP, Strong EW. The significance of “positive” margins in surgically resected epidermoid carcinomas. Head Neck Surg 1978;1:107111.

    • Search Google Scholar
    • Export Citation
  • 67

    Johnson JT, Barnes EL, Myers EN. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol 1981;107:725729.

  • 68

    Feldman M, Fletcher GH. Analysis of the parameters relating to failures above the clavicles in patients treated by postoperative irradiation for squamous cell carcinomas of the oral cavity or oropharynx. Int J Radiat Oncol Biol Phys 1982;8:2730.

    • Search Google Scholar
    • Export Citation
  • 69

    Mirimanoff RO, Wang CC, Doppke KP. Combined surgery and postoperative radiation therapy for advanced laryngeal and hypopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 1985;11:499504.

    • Search Google Scholar
    • Export Citation
  • 70

    Peters LJ, Goepfert H, Ang KK. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993;26:311.

    • Search Google Scholar
    • Export Citation
  • 71

    Thames HD Jr, Withers HR, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982;8:219226.

    • Search Google Scholar
    • Export Citation
  • 72

    Withers H, Thames H, Peters L. Differences in the fractionation response of acutely and late-responding tissues. In: Kaercher K, Kogelnik H, Reinartz G, eds. Progress in Radio-Oncology II. Vol. 11. New York, NY: Raven Press; 1982:287296.

    • Search Google Scholar
    • Export Citation
  • 73

    Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131146.

  • 74

    Harwood AR, Beale FA, Cummings BJ. T4NOMO glottic cancer: an analysis of dose-time volume factors. Int J Radiat Oncol Biol Phys 1981;7:15071512.

    • Search Google Scholar
    • Export Citation
  • 75

    Amornmarn R, Prempree T, Viravathana T. A therapeutic approach to early vocal cord carcinoma. Acta Radiol Oncol 1985;24:321325.

  • 76

    Schwaibold F, Scariato A, Nunno M. The effect of fraction size on control of early glottic cancer. Int J Radiat Oncol Biol Phys 1988;14:451454.

    • Search Google Scholar
    • Export Citation
  • 77

    Kim RY, Marks ME, Salter MM. Early-stage glottic cancer: importance of dose fractionation in radiation therapy. Radiology 1992;182:273275.

  • 78

    Parson J. Time-dose-volume relationships in radiation therapy. In: Million R, Cassisi N, eds. Management of Head and Neck Cancer: A Multidisciplinary Approach, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1994:203243.

    • Search Google Scholar
    • Export Citation
  • 79

    Horiot JC, Le Fur R, N’Guyen T. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231241.

    • Search Google Scholar
    • Export Citation
  • 80

    Horiot JC. [Controlled clinical trials of hyperfractionated and accelerated radiotherapy in otorhinolaryngologic cancers]. Bull Acad Natl Med 1998;182:12471260; discussion 1261 [in French].

    • Search Google Scholar
    • Export Citation
  • 81

    Horiot JC, Bontemps P, van den Bogaert W. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111121.

    • Search Google Scholar
    • Export Citation
  • 82

    Fu KK, Pajak TF, Trotti A. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:716.

    • Search Google Scholar
    • Export Citation
  • 83

    Trotti A, Fu K, Pajak T. Long term outcomes of RTOG 90-03: a comparison of hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma [abstract]. Int J Radiat Oncol Biol Phys 2005;63:S7071.

    • Search Google Scholar
    • Export Citation
  • 84

    Bourhis J, Overgaard J, Audry H. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843854.

    • Search Google Scholar
    • Export Citation
  • 85

    Budach V, Stuschke M, Budach W. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005;23:11251135.

    • Search Google Scholar
    • Export Citation
  • 86

    Budach W, Hehr T, Budach V. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006;6:28.

    • Search Google Scholar
    • Export Citation
  • 87

    Bensadoun RJ, Benezery K, Dassonville O. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006;64:983994.

    • Search Google Scholar
    • Export Citation
  • 88

    Brizel DM, Albers ME, Fisher SR. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:17981804.

    • Search Google Scholar
    • Export Citation
  • 89

    Jeremic B, Shibamoto Y, Milicic B. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:14581464.

    • Search Google Scholar
    • Export Citation
  • 90

    Ang K, Zhang Q, Wheeler RH. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 5507.

    • Search Google Scholar
    • Export Citation
  • 91

    Denis F, Garaud P, Bardet E. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:6976.

    • Search Google Scholar
    • Export Citation
  • 92

    Denis F, Garaud P, Bardet E. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003;55:9398.

    • Search Google Scholar
    • Export Citation
  • 93

    Bourhis J, Calais G, Lapeyre M. Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC). Semin Oncol 2004;31:822826.

    • Search Google Scholar
    • Export Citation
  • 94

    Machtay M, Moughan J, Trotti A. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:35823589.

    • Search Google Scholar
    • Export Citation
  • 95

    Hartford AC, Palisca MG, Eichler TJ. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys 2009;73:914.

    • Search Google Scholar
    • Export Citation
  • 96

    Holmes T, Das R, Low D. American Society of Radiation Oncology recommendations for documenting intensity-modulated radiation therapy treatments. Int J Radiat Oncol Biol Phys 2009;74:13111318.

    • Search Google Scholar
    • Export Citation
  • 97

    Wu Q, Manning M, Schmidt-Ullrich R, Mohan R. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys 2000;46:195205.

    • Search Google Scholar
    • Export Citation
  • 98

    Chao KS, Majhail N, Huang CJ. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001;61:275280.

    • Search Google Scholar
    • Export Citation
  • 99

    Dogan N, King S, Emami B. Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. Int J Radiat Oncol Biol Phys 2003;57:14801491.

    • Search Google Scholar
    • Export Citation
  • 100

    Li Y, Taylor JM, Ten Haken RK, Eisbruch A. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 2007;67:660669.

    • Search Google Scholar
    • Export Citation
  • 101

    Pow EH, Kwong DL, McMillan AS. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006;66:981991.

    • Search Google Scholar
    • Export Citation
  • 102

    Kam MK, Leung SF, Zee B. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007;25:48734879.

    • Search Google Scholar
    • Export Citation
  • 103

    Pfister D, Cassileth B, Deng G. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol 2010;28:25652570.

    • Search Google Scholar
    • Export Citation
  • 104

    Scarantino C, LeVeque F, Swann RS. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol 2006;4:252258.

    • Search Google Scholar
    • Export Citation
  • 105

    Petrone D, Condemi JJ, Fife R. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002;46:748754.

    • Search Google Scholar
    • Export Citation
  • 106

    Galvin JM, De Neve W. Intensity modulating and other radiation therapy devices for dose painting. J Clin Oncol 2007;25:924930.

  • 107

    Lauve A, Morris M, Schmidt-Ullrich R. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II—clinical results. Int J Radiat Oncol Biol Phys 2004;60:374387.

    • Search Google Scholar
    • Export Citation
  • 108

    Schoenfeld GO, Amdur RJ, Morris CG. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008;71:377385.

    • Search Google Scholar
    • Export Citation
  • 109

    Lee NY, de Arruda FF, Puri DR. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66:966974.

    • Search Google Scholar
    • Export Citation
  • 110

    de Arruda FF, Puri DR, Zhung J. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006;64:363373.

    • Search Google Scholar
    • Export Citation
  • 111

    Garden AS, Morrison WH, Wong PF. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007;67:438444.

    • Search Google Scholar
    • Export Citation
  • 112

    Eisbruch A, Levendag PC, Feng FY. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. Int J Radiat Oncol Biol Phys 2007;69:S4042.

    • Search Google Scholar
    • Export Citation
  • 113

    Wolden SL, Chen WC, Pfister DG. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006;64:5762.

    • Search Google Scholar
    • Export Citation
  • 114

    Madani I, Bonte K, Vakaet L. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys 2009;73:424432.

    • Search Google Scholar
    • Export Citation
  • 115

    Eisbruch A. Reducing xerostomia by IMRT: what may, and may not, be achieved. J Clin Oncol 2007;25:48634864.

  • 116

    Hodge CW, Bentzen SM, Wong G. Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison. Int J Radiat Oncol Biol Phys 2007;69:10321041.

    • Search Google Scholar
    • Export Citation
  • 117

    Veldeman L, Madani I, Hulstaert F. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008;9:367375.

    • Search Google Scholar
    • Export Citation
  • 118

    Eisbruch A, Marsh LH, Dawson LA. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 2004;59:2842.

    • Search Google Scholar
    • Export Citation
  • 119

    Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 2009;19:2934.

  • 120

    Gomez DR, Zhung JE, Gomez J. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys 2009;73:10961103.

    • Search Google Scholar
    • Export Citation
  • 121

    Lee NY, O’Meara W, Chan K. Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 2007;69:459468.

    • Search Google Scholar
    • Export Citation
  • 122

    Nutting CM, Morden JP, Harrington KJ. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 201112:127136.

    • Search Google Scholar
    • Export Citation
  • 123

    Nutting C, A’Hern R, Rogers MS. First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005) [abstract]. J Clin Oncol 2009;27(Suppl 18):Abstract LBA6006.

    • Search Google Scholar
    • Export Citation
  • 124

    Posner MR, Ervin TJ, Miller D. Incidence of hypothyroidism following multimodality treatment for advanced squamous cell cancer of the head and neck. Laryngoscope 1984;94:451454.

    • Search Google Scholar
    • Export Citation
  • 125

    Fleming AJ Jr, Smith SP Jr, Paul CM. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007;117:11731179.

    • Search Google Scholar
    • Export Citation
  • 126

    Branstetter BF, Blodgett TM, Zimmer LA. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005;235:580586.

  • 127

    Nasman A, Attner P, Hammarstedt L. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125:362366.

    • Search Google Scholar
    • Export Citation
  • 128

    Hammarstedt L, Lindquist D, Dahlstrand H. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006;119:26202623.

    • Search Google Scholar
    • Export Citation
  • 129

    Ang KK, Harris J, Wheeler R. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:2435.

  • 130

    Fakhry C, Westra WH, Li S. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261269.

    • Search Google Scholar
    • Export Citation
  • 131

    Gillison ML, Harris J, Westra W. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129 [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 6003.

    • Search Google Scholar
    • Export Citation
  • 132

    Rischin D, Young R, Fisher R. Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 6004.

    • Search Google Scholar
    • Export Citation
  • 133

    Lassen P, Eriksen JG, Hamilton-Dutoit S. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:19921998.

    • Search Google Scholar
    • Export Citation
  • 134

    Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007;121:18131820.

    • Search Google Scholar
    • Export Citation
  • 135

    Rischin D, Young RJ, Fisher R. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28:41424148.

    • Search Google Scholar
    • Export Citation
  • 136

    Begum S, Gillison ML, Nicol TL, Westra WH. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:11861191.

    • Search Google Scholar
    • Export Citation
  • 137

    Vokes EE, Stenson K, Rosen FR. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003;21:320326.

    • Search Google Scholar
    • Export Citation
  • 138

    Hitt R, Grau J, Lopez-Pousa A. Phase II/III trial of induction chemotherapy (ICT) with cisplatin/5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for unresectable locally advanced head and neck cancer (LAHNC) [abstract]. J Clin Oncol 2005;23(Suppl 16):Abstract 5578.

    • Search Google Scholar
    • Export Citation
  • 139

    Hitt R, Lopez-Pousa A, Martinez-Trufero J. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:86368645.

    • Search Google Scholar
    • Export Citation
  • 140

    Hitt R, Grau J, Lopez-Pousa A. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC) [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 5515.

    • Search Google Scholar
    • Export Citation
  • 141

    Posner MR, Hershock DM, Blajman CR. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:17051715.

    • Search Google Scholar
    • Export Citation
  • 142

    Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949955.

    • Search Google Scholar
    • Export Citation
  • 143

    Paccagnella A, Orlando A, Marchiori C. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265272.

    • Search Google Scholar
    • Export Citation
  • 144

    Lorch JH, Goloubeva O, Haddad RI. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011;12:152159.

    • Search Google Scholar
    • Export Citation
  • 145

    Vermorken JB, Remenar E, van Herpen C. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:16951704.

    • Search Google Scholar
    • Export Citation
  • 146

    Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:414.

    • Search Google Scholar
    • Export Citation
  • 147

    Lefebvre JL, Chevalier D, Luboinski B. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890899.

    • Search Google Scholar
    • Export Citation
  • 148

    Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:16851690.

    • Search Google Scholar
    • Export Citation
  • 149

    McNeil BJ, Weichselbaum R, Pauker SG. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med 1981;305:982987.

    • Search Google Scholar
    • Export Citation
  • 150

    Adelstein DJ, Li Y, Adams GL. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:9298.

    • Search Google Scholar
    • Export Citation
  • 151

    Lo TC, Wiley AL Jr, Ansfield FJ. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol 1976;126:229235.

    • Search Google Scholar
    • Export Citation
  • 152

    Sanchiz F, Milla A, Torner J. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:13471350.

    • Search Google Scholar
    • Export Citation
  • 153

    Browman GP, Cripps C, Hodson DI. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994;12:26482653.

    • Search Google Scholar
    • Export Citation
  • 154

    Smid L, Lesnicar H, Zakotnik B. Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer—preliminary report. Int J Radiat Oncol Biol Phys 1995;32:769775.

    • Search Google Scholar
    • Export Citation
  • 155

    Merlano M, Benasso M, Corvo R. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88:583589.

    • Search Google Scholar
    • Export Citation
  • 156

    Wendt TG, Grabenbauer GG, Rodel CM. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:13181324.

    • Search Google Scholar
    • Export Citation
  • 157

    Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:8391.

  • 158

    El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996;14:838847.

    • Search Google Scholar
    • Export Citation
  • 159

    Bourhis J, Amand C, Pignon JP. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy [abstract]. J Clin Oncol 2004;22(Suppl 14):Abstract 5505.

    • Search Google Scholar
    • Export Citation
  • 160

    Pignon JP, le Maitre A, Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69:S112114.

    • Search Google Scholar
    • Export Citation
  • 161

    Forastiere AA, Goepfert H, Maor M. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:20912098.

    • Search Google Scholar
    • Export Citation
  • 162

    Argiris A, Haraf DJ, Kies MS, Vokes EE. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist 2003;8:350360.

    • Search Google Scholar
    • Export Citation
  • 163

    Pointreau Y, Garaud P, Chapet S. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498506.

    • Search Google Scholar
    • Export Citation
  • 164

    Paccagnella A, Ghi MG, Loreggian L. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010;21:15151522.

    • Search Google Scholar
    • Export Citation
  • 165

    Hitt R, Grau JJ, Lopez-Pousa A. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC) [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 6009.

    • Search Google Scholar
    • Export Citation
  • 166

    Salama JK, Haddad RI, Kies MS. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;75:725733.

    • Search Google Scholar
    • Export Citation
  • 167

    Lefebvre J, Pointreau Y, Rolland F. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 6010.

    • Search Google Scholar
    • Export Citation
  • 168

    Buiret G, Combe C, Favrel V. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010;77:430437.

    • Search Google Scholar
    • Export Citation
  • 169

    Nutting CM, Bhide SA, Harrington KJ. Treatment of head and neck cancer. N Engl J Med 2008;358:10761077; author reply 1077–1078.

  • 170

    Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 2007;43:13991406.

    • Search Google Scholar
    • Export Citation
  • 171

    Kies MS, Holsinger FC, Lee JJ. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010;28:814.

    • Search Google Scholar
    • Export Citation
  • 172

    Kotwall C, Sako K, Razack MS. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 1987;154:439442.

  • 173

    Lefebvre JL, Rolland F, Tesselaar M. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009;101:142152.

    • Search Google Scholar
    • Export Citation
  • 174

    Cooper JS, del Rowe J, Newall J. Regional stage IV carcinoma of the nasopharynx treated by aggressive radiotherapy. Int J Radiat Oncol Biol Phys 1983;9:17371745.

    • Search Google Scholar
    • Export Citation
  • 175

    Bailet JW, Mark RJ, Abemayor E. Nasopharyngeal carcinoma: treatment results with primary radiation therapy. Laryngoscope 1992;102:965972.

  • 176

    Johansen LV, Mestre M, Overgaard J. Carcinoma of the nasopharynx: analysis of treatment results in 167 consecutively admitted patients. Head Neck 1992;14:200207.

    • Search Google Scholar
    • Export Citation
  • 177

    Sanguineti G, Geara FB, Garden AS. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 1997;37:985996.

    • Search Google Scholar
    • Export Citation
  • 178

    Wang C. Radiation Therapy for Head and Neck Neoplasms, 3rd ed. New York, NY: Wiley-Liss; 1997.

  • 179

    Al-Sarraf M, LeBlanc M, Giri PG. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:13101317.

    • Search Google Scholar
    • Export Citation
  • 180

    Mesic JB, Fletcher GH, Goepfert H. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys 1981;7:447453.

    • Search Google Scholar
    • Export Citation
  • 181

    Hoppe RT, Goffinet DR, Bagshaw MA. Carcinoma of the nasopharynx. Eighteen years’ experience with megavoltage radiation therapy. Cancer 1976;37:26052612.

    • Search Google Scholar
    • Export Citation
  • 182

    Wee J, Tan EH, Tai BC. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:67306738.

    • Search Google Scholar
    • Export Citation
  • 183

    Chan AT, Leung SF, Ngan RK. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536539.

    • Search Google Scholar
    • Export Citation
  • 184

    Leong SS, Wee J, Tay MH. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase II trial using a triplet combination. Cancer 2005;103:569575.

    • Search Google Scholar
    • Export Citation
  • 185

    Chan AT, Hsu MM, Goh BC. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:35683576.

    • Search Google Scholar
    • Export Citation
  • 186

    Zhang L, Zhang Y, Huang PY. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 2008;61:3338.

    • Search Google Scholar
    • Export Citation
  • 187

    Ngan RK, Yiu HH, Lau WH. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 2002;13:12521258.

    • Search Google Scholar
    • Export Citation
  • 188

    Ma BB, Tannock IF, Pond GR. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 2002;95:25162523.

    • Search Google Scholar
    • Export Citation
  • 189

    Bonner JA, Harari PM, Giralt J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567578.

  • 190

    Garden AS, Harris J, Vokes EE. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:28562864.

    • Search Google Scholar
    • Export Citation
  • 191

    Garden AS, Harris J, Vokes EE. Results of Radiation Therapy Oncology Group 97-03—a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck: long-term results and late toxicities [abstract]. Int J Radiat Oncol Biol Phys 2007;69:S140.

    • Search Google Scholar
    • Export Citation
  • 192

    Vermorken JB, Trigo J, Hitt R. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:21712177.

    • Search Google Scholar
    • Export Citation
  • 193

    Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:26442652.

    • Search Google Scholar
    • Export Citation
  • 194

    Forastiere AA, Shank D, Neuberg D. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:22702274.

    • Search Google Scholar
    • Export Citation
  • 195

    Gibson MK, Li Y, Murphy B. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:35623567.

    • Search Google Scholar
    • Export Citation
  • 196

    Forastiere AA, Metch B, Schuller DE. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:12451251.

    • Search Google Scholar
    • Export Citation
  • 197

    Vermorken JB, Mesia R, Rivera F. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:11161127.

  • 198

    Samlowski WE, Moon J, Kuebler JP. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group phase II study. Cancer Invest 2007;25:182188.

    • Search Google Scholar
    • Export Citation
  • 199

    Burtness B, Goldwasser MA, Flood W. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:86468654.

    • Search Google Scholar
    • Export Citation
  • 200

    Jacobs C, Lyman G, Velez-Garcia E. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257263.

    • Search Google Scholar
    • Export Citation
  • 201

    Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol 1994;21:311319.

    • Search Google Scholar
    • Export Citation
  • 202

    Clavel M, Vermorken JB, Cognetti F. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5:521526.

    • Search Google Scholar
    • Export Citation
  • 203

    Stewart JS, Cohen EE, Licitra L. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27:18641871.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 980 470 22
PDF Downloads 168 109 9
EPUB Downloads 0 0 0